Business Context and Reporting Period
This Form 6-K filing by BioNTech SE covers the month of September 2026, specifically dated September 18, 2026. The report announces a corporate governance update regarding the appointment of a new independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate announcement and does not contain financial performance data.
Material Changes
The primary material change disclosed is the decision to replace the current independent auditor. The Supervisory Board has approved the appointment of KPMG AG Wirtschaftsprüfungsgesellschaft as the new independent auditor for the financial year ending December 31, 2027.
Guidance, Outlook, and Management Commentary
- Audit Tender Process: The appointment follows a comprehensive and competitive audit tender process overseen by the Audit Committee of the Supervisory Board.
- Selection Criteria: Participating firms were evaluated against predefined criteria, leading to a unanimous recommendation by the Audit Committee.
- Governance Rationale: Management notes that while BioNTech is not subject to mandatory auditor rotation, periodically reassessing external audit arrangements aligns with good governance practices.
- Next Steps: The appointment is subject to election by shareholders at the upcoming Annual General Meeting.
Investor Verification Checklist
- Confirm the outcome of the shareholder vote at the upcoming Annual General Meeting regarding the KPMG appointment.
- Verify the transition timeline and any potential impact on the audit of the 2026 financial statements.
- Review the competitive tender process details if further disclosure is provided in future filings.